We demonstrated in the present study that the BCL-6 tranof B cell maturation. However, it is still uncertain whether scripts were detectable not only in B cells, but also in circulat-BCL-6 protein may be expressed during the differentiation of atmosphere with 5% CO 2 at 37°C.
Introduction
For differentiation studies, exponentially growing cells were plated at a density of 5 × 10 5 /ml. The cells were induced to Chromosomal translocations involving 3q27 have been differentiate in the presence of either 1.6% v/v dimethyl sulreported to be associated with certain types of non-Hodgkin's foxide (DMSO; Merck, Darmstadt, Germany), 10 ng/ml 12-⌷-lymphoma (NHL). 1, 2 Recently, break point regions of 3q27 in tetradecanoylphorbol-13-acetate (TPA; Sigma, St Louis, MO, NHLs have been cloned by four independent groups [3] [4] [5] [6] and USA), respectively. Optimal doses of these reagents were subsequently a candidate proto-oncogene BCL-6 was identdetermined by preliminary experiments (data not shown). ified at 3q27. [7] [8] [9] Since the breakpoints at 3q27 previously reported were clustered around the first exon, 10-12 BCL-6 gene rearrangement reported in NHLs appears to cause trans-RNA extraction and Northern blotting criptional deregulation which may contribute to lymphomagenesis. 13, 14 Total RNA was extracted using the RNAzol B method (Biotecx The BCL-6 gene has been reported to encode 706 amino Laboratories, Houston, TX, USA), which is based on a acids. The residues corresponding to the COOH-terminal modified acid guanidinium thiocyanate-phenol-chloroform region contain six C 2 H 2 zinc finger motifs which are known method. 21 The 1FR probe corresponding to the BCL-6 cDNA as a DNA or protein binding domain. While the residues corwas prepared using the reverse transcriptase-polymerase responding to the NH2-terminal region contain BTB/POZ chain reaction (RT-PCR) as reported previously. 17 For Northdomain which is thought to act as a protein-protein interacern blotting, 20 g of total RNA was electrophoresed through tion domain, 15, 16 suggesting that BCL-6 protein may function 1% w/v agarose gel containing 3% v/v formaldehyde and then as a transcriptional factor. [7] [8] [9] We have recently found that the transferred to a nylon membrane (Pall Biodyne Transfer Mem-BCL-6 protein is highly expressed in germinal center B cells brane; PALL Biosupport, East Hills, NY, USA). The membrane as a 92-to 98-kDa nuclear protein, whereas its expression is was hybridized at 42°C with the 1FR-probe, which was labvery low or undetectable in marginal zone B cells, mantle eled RNA were transferred. The intensity of the signal was evalufragment of BCL-6 cDNA and a 1.9 kb BamHI-PstI fragment of human ␤-actin cDNA (pHF␤A-1) were cloned into the ated by densitometric scanning of the autoradiograms using an SP-500 image analyzer (Olympus, Tokyo, Japan).
PUC118 or PUC119 vector. Single-stranded DNAs were prepared using the M13 KO7 helper phage according to the methods described previously. 24 Then the dot-blotted filters were prepared similarly as described above.
Treatment of cells with actinomycin D (ACD)
To measure the half-life of BCL-6 mRNA, U937 cells were Hybridization conditions:
The filters were prehybridized treated with 10 ng/ml TPA for 24 h prior to exposure to ACD for 12 h at 65°C in prehybridization buffer (10 mmol/l TES, (10 g/ml), an inhibitor of RNA synthesis. The cells were incu-0.33 mol/l NaCl, 10 mmol/l EDTA, 0.2% SDS, 50 g/ml bated for 0, 1, 2, 4, 6 and 8 h, respectively, after the addition tRNA, 50 g/ml salmon sperm DNA, 0.05% sodium pyroof ACD, then harvested and subjected to Northern blotting.
phosphate and 2× Denhardt's solution). Equal numbers of ethanol-precipitable counts (c.p.m.) transcribed from the untreated and TPA-treated nuclei were hybridized to triplicate Treatment of cells with cycloheximide filters for 4 h at 65°C in hybridization buffer (10 mmol/ml pH 7.4, 0.33 mol/l NaCl, 10 mmol/l EDTA, 0.2% SDS), and To clarify whether de novo synthesis of certain proteins is the filters were washed in 0.2× SSC and 0.1% SDS for 30 min required for the induction of BCL-6 mRNA expression with at 60°C. TPA, U937 cells were treated with 10 ng/ml TPA and 10 g/ml cycloheximide (CHX) and then incubated for 0, 1, 3, 6, 9, 12 and 24 h. The cells were then harvested and subCalculation of transcription rates of BCL6 and the ␤-actin jected to Northern blotting.
gene:
The intensity of the signals obtained was assessed using a BAS2000 Bio-image analyzer (Fuji Photo Film, Tokyo, Japan). The transcription rate (TR) was calculated as follows:
Nuclear run-on transcription assay
Nuclear run-on assays were performed using basically the where TPA-Sig = signals obtained from TPA-treated U-937 same techniques as those reported previously. Morphologic subtypes of acute leukemias were determined stop buffer (10% N-lauroylsarcosine sodium salt, 0.1 mol/l according to the French-American-British (FAB) classification EDTA, 0.1 mol/l Tris-HCl pH 7.5, 1 mg/ml proteinase K) and criteria. 25 In order to investigate the expression of BCL-6 15 g yeast tRNA were added and incubated at 42°C for 30 mRNA in human leukemia cells, bone marrow aspirates were min. The reaction mixture was finally extracted with phenolobtained from patients with various leukemias, except for one chloroform and ethanol-precipitated twice.
patient with ATL, whose peripheral blood was used as a source of tumor cells. Bone marrow aspiration was performed as part of a diagnostic procedure, and informed consent was Double-strand DNA dot-blot preparation:
A 2.1 kb EcoRI obtained from the patients. Experimental protocols were fragment of BCL-6 cDNA 17 and a 1.9 kb BamHI-PstI fragment approved beforehand by the institutional ethics committee. of human ␤-actin cDNA (pHF␤A-1) 23 were gel-purified. Five Samples were obtained before chemotherapy, and monomicrograms of insert DNA was denatured in 0.3 mol/l NaOH nuclear cells were isolated by the Ficoll-Hypaque density for 1 h at 65°C and then neutralized with 2 mol/l NH 4 OAc. gradient centrifugation method. Total RNA was extracted by The DNA was filtered through a dot-blot apparatus (ATTO Co, the method described above. Tokyo, Japan) onto a nylon membrane (Biodyne Transfer Membrane Biodyne B; PALL BioSupport) under vacuum and then the filter was UV-cross-linked. Duplicate filters were prePreparation of peripheral blood T cells, B cells, pared for uninduced and TPA-induced U-937 cells.
monocytes and granulocytes
Peripheral blood T cells and B cells were collected from healthy volunteers using anti-CD3 or CD20 monoclonal antibody Single-strand DNA dot-blot preparation:
A 2.1 kb EcoRI
Figure 2
Induction of BCL-6 transcripts in peripheral granulocytes by TPA. Peripheral granulocytes were purified as described in Materials and methods. Twenty micrograms of total RNA extracted from granulocytes before (0) and 10 min (10) after stimulation with TPA was subjected to electrophoresis and Northern blotting.
the CD20
+ B cells was more than 89%, respectively, and the purity of monocytes and granulocytes was shown to be more than 80%, respectively. The signals of BCL-6 and ␤-actin mRNA were quantified by using the densitometer and were evaluated in the ratio of the BCL-6 signals to the ␤-actin signals. The calculated ratios (BCL-6:␤-actin) were: monocytes,
Figure 1
Northern cytes and granulocytes as well as in T and B cells (Figure 1 ). Furthermore, we examined whether the BCL-6 expression might be upregulated or downregulated when the peripheral (mAb) (Dakopatts, Copenhagen, Denmark) and Dynabeads M-450 goat anti-mouse IgG (Dynal, Oslo, Norway). The percentgranulocytes were stimulated with TPA. The calculated ratio of the signals (BCL-6:␤-actin) was increased up to 1.70 after ages of T and B cells were measured by the positive rate of CD3 and CD20 antigen-expressing cells, respectively. Periph-TPA-stimulation ( Figure 2) . Next, leukemic cells were freshly obtained from bone mareral monocytes 26 and granulocytes 27 were collected according to the methods described previously. The purity of grarow of patients with acute nonlymphocytic leukemia (ANLL) (Figure 3 ). Morphological study showed that the mononuclear nulocytes was confirmed by morphological observation of collected cells stained by the Giemsa solution. The purity of cells in the leukemic samples contained Ͼ90% leukemic blasts. As shown in Table 1 , six of 16 cases of ANLL were monocytes was calculated as follows: the collected cells were first cultured on a slide chamber for 2 h and the number of found to express BCL-6 transcripts, while four of the six positive patients were found to have a monocytic phenotype. adherent cells counted. Subsequently, the adherent cells were stained for peroxidase with 3.3′-diaminobenzidine (DAB)
Meanwhile, BCL-6 expression was not observed in M1, M2 or M6. In addition, two cases of APL (M3) were found to (Sigma). The number of positively stained cells was counted and the positive rate (peroxidase positive cells/adherent cells) express BCL-6 transcripts, although the expression level remained very low in one. These results suggest that the was calculated. Total RNAs extracted from these samples were subjected to Northern blotting, as described above.
expression of BCL-6 gene may be associated with monocytic lineage and a particular stage of differentiation in granulocytic lineage.
Results
Expression of the BCL-6 gene in human leukemia and BCL-6 transcripts are induced during monocytic differentiation in HL-60 and U-937 cells normal blood Northern blot analysis of BCL-6 transcripts in adult human leukemias. Total RNA was extracted from mononuclear cells isolated from bone marrow aspirates of various leukemia patients. Ten micrograms of total RNA was subjected to electrophoresis, and Northern blotting was performed as described in Materials and methods.
Table 1
Expression of BCL-6 mRNA in adult human leukemias TPA for previous 24 h, the level of BCL-6 mRNA began to increase 3 h after CHX treatment, peaked at 6 h, and then declined thereafter (data not shown). These results suggest that both cell lines along the monocytic lineage by treatment with CHX superinduces BCL-6 gene expression, and that de novo TPA. The differentiated cells were identified by cell-surface protein synthesis is not required for the induction of BCL-6 expression of CD14 protein with FACS analysis. 28, 29 Both HLmRNA with TPA. 60 and U-937 cells expressed CD14 by treatment with TPA, consistent with the results reported previously. 29 Northern blot analysis before the induction of differentiation showed that the Transcriptional and post-transcriptional up-regulation BCL-6 transcripts were not detectable in HL60 cells and that of BCL-6 gene expression only a trace level of BCL-6 transcripts was detected in U-937 cells. On the other hand, HL-60 and U-937 cells exposed to TPA exhibited a weak signal of BCL-6 mRNA 3 h after To study whether the induction of BCL-6 gene expression during monocytic differentiation was transcriptionally regulated, exposure, and the signals gradually increased and reached a peak level at 24 h after TPA treatment (Figure 4) . The steadyindependent quadruplicate nuclear run-on assays were performed using nuclei isolated from untreated and TPA-treated state level of BCL-6 trasncript expression continued for at least 72 h after TPA treatment (data not shown). Thus, the up-regu-U-937 cells. There were small increases in the transcription signals of the BCL-6 gene by TPA treatment (1.82-fold, 1.51-lation of BCL-6 gene expression appears to be associated with monocytoid differentiation. These results were consistent with fold, 2.58-fold and 1.05-fold) (Figure 6 ), suggesting that the transcriptional activation may be a part of the mechanism of the data obtained by analyzing the samples of leukemia patients. Meanwhile, when HL-60 cells were induced to dif-TPA-induced accumulation of BCL-6 mRNA in U-937 cells.
In order to study the post-transcriptional regulation of TPAferentiate along the granulocytic lineage with DMSO, BCL-6 mRNA was also detected (Figure 4) . But the level of expression induced BCL-6 mRNA levels, U-937 cells were treated with TPA for 24 h to induce BCL-6 gene expression and then exposed to ACD. The signals corresponding to BCL-6 tran- half-life of BCL-6 mRNA in induced U-937 cells was 2.8 h.
plus CHX (10 g/ml) and total RNAs were isolated at the indicated time after treatment; bottom panel: U-937 cells were treated with CHX Furthermore, when U-937 cells pretreated with TPA for 24 h (10 g/ml) and total RNAs were isolated at the indicated time after were exposed to CHX in addition to ACD, the signals could treatment.
be detected until at least 6 h after exposure, with a calculated half-life of 5.4 h. This prolonged half-life of BCL-6 mRNA upon addition of CHX suggests that CHX may affect BCL-6 gene expression through a post-transcriptional mechanism 60 and U-937 cells by TPA stimulation. Furthermore, BCL-6 was preferably expressed in human acute leukemias with involving the synthesis of a protein which may affect the stability of the BCL-6 mRNA. monocytic (M5) or granulocytic (M3) phenotype. These data apparently suggest that the expression of BCL-6 in myeloid/monocytoid cells is associated with differentiation. Thus, it is suggested that BCL-6 may be expressed and funcDiscussion tion in the particular differentiation step of T and B lymphocytes, granulocytes and monocytes. We recently reported that the expression of BCL-6 protein was very high in germinal center B cells, but very low or undetectIt has recently been reported that the stimulation of B cells with a variety of agents including LPS, PMA, anti-IgM antiable in the other B cells such as marginal zone B cells, mantle zone B cells or plasma cells. 17 However, the present study has bodies, CD40 ligand or CD40 ligand plus anti-IgM antibodies was found to down-regulate the BCL-6 expression. 32 Also in demonstrated that the BCL-6 gene expression was not limited to B cell lineage but its expression was also found in the other T cells, BCL-6 was found to be down-regulated after stimulation with PHA. 32 In contrast to these reports on T and B lineages such as myeloid/monocytoid cells and T cells. In CD4 + T cells, BCL-6 has recently been reported to be lymphocytes, the activation of peripheral granulocytes with TPA in our present study resulted in the up-regulation of BCLexpressed.
30,31
Concerning the bone marrow-derived myeloid/monocytoid cells, we found in the present study that 6 mRNA, suggesting that up-or down-regulation of BCL-6 in cellular activation may be dependent on each cell type. the peripheral granulocytes and monocytes express BCL-6 mRNA. We also found that BCL-6 gene expression was
Further analysis using anti-sense oligo-single stranded DNA to interrupt the BCL-6 gene expression or analysis of BCL-6 geneinduced during monocytic lineage differentiation in both HL- 
